Decrease in Paraoxonase Enzyme Level and Myocardial İnfarction

NCT04243876 | Completed

• 1 other identifier: 20/9
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

Myocardial infarction is a polygenic disease that may occur due to various environmental risk factors. Mortality risk of the disease; sex, age, smoking, systolic blood pressure, total cholesterol, and high-density lipoprotein levels. The paraoxonase-1 phenotype is expressed as the paraoxonase/arylesterase ratio and is closely related to high-density lipoprotein, acting as an endogenous defense mechanism against vascular oxidative stress, thus contributing to the prevention of atherosclerosis. Serum concentration and activity depend on environmental factors as well as genetic polymorphism. This decrease in enzyme concentration causes changes in gene expression (1). Numerous data on Paraoxonase-1 levels have been found in studies, especially with decreasing serum paraoxonase and arylesterase activities with age, associated with increased risk of systemic oxidative stress and atherosclerosis in humans. Many studies have shown that serum Paraoxonase-1 activity is significantly reduced in people with myocardial infarction, dyslipidemia, atherosclerosis, and chronic kidney disease. The most important risk factor for these and similar diseases is aging. Diversity of conditions such as genetic predisposition, malnutrition, stress, and smoking, which increases vascular dysfunction due to oxidative stress, classify individuals with acute myocardial infarction according to age groups and investigate whether there is a relationship between serum Paraoxonase-1 activity and severity of coronary artery disease in young patients. The paraoxonase-1 enzyme, which is known to decrease blood levels with age, is found to be significantly lower in patients with myocardial infarction at a young age compared to the healthy control group.

Conditions

Myocardial Infarction; High-Density Lipoid Deficiency

Keywords

Myocardial infarction, Paraoxonase

Outcome Measures

Primary Outcomes (1)

• early diagnosis

  paraoxonase enzyme measurement

  one year

Study Arms (2)

paraoxanase

Enzyme level

Diagnostic Test: paraoxanase enzyme level

Myocardial infarction

RESULTS OF ANGIOGRAPHY

Diagnostic Test: paraoxanase enzyme level

Interventions

paraoxanase enzyme level DIAGNOSTIC_TEST

presence of paraoxonase enzyme deficiency and associated troponin elevation

Also known as: troponin level, HDL level

Myocardial infarction; paraoxanase

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

All patients admitted to the emergency department over the age of 18

You may qualify if:

• Those over the age of 18
• All acute coronary syndrome patients

You may not qualify if:

• \- Patients with normal angiography

Sponsors & Collaborators

• Bezmialem Vakif University: lead

Study Sites (1)

Bezmialem vakif university

Istanbul, Eyalet/Yerleşke, 34093, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Myocardial Infarction; Hypoalphalipoproteinemias

Condition Hierarchy (Ancestors)

Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Infarction; Ischemia; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Necrosis; Hypolipoproteinemias; Lipid Metabolism, Inborn Errors; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Dyslipidemias; Lipid Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• bahadir taslidere

  BEZMİALEM VAKİF UNİVERSİTY

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor, clinical research

Study Record Dates

• First Submitted: December 31, 2019
• First Posted: January 28, 2020
• Study Start: December 30, 2019
• Primary Completion: May 27, 2022
• Study Completion: May 27, 2022
• Last Updated: May 31, 2022

Record last verified: 2022-05

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)